Merck has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization.
Someone at Merck has an interesting sense of humor.
A couple of weeks ago, I wrote that, given the choice, I still wanted the Red Pill. My comment was directed to health care choices, but James Delingpole writes in The Telegraph (H/T, Instapundit) that a Red Pill/Blue Pill choice also needs to made about economics as well. And soon. Very soon.
Quite how bad things get in the next few weeks and years really depends on how quickly the red pill faction manages to win the political and economic arguments. At the moment, the blue pill faction holds sway everywhere from Ben Bernanke’s Fed to Osborne’s Treasury to the entire crumbling mechanism of the EU. Given most people’s reluctance to deal with reality, I wouldn’t bank on a remotely happy outcome.
Read the whole thing.
UPDATE—Breitbart has a post up about 10 bad news economics stories that the MSM is downplaying.